Listed as number three in pharma sales, GlaxoSmithKline has had some rough luck thanks in part to the diabetes drug Avandia, which has been pulled out of Europe and restricted in the U.S after global side effect concerns since 2007. The company cut its losses on the drug, writing off $233 million in supplies and eliminating its marketing efforts of the drug.

The company has racked up some charges against its earnings, including over $6 billion in the fourth quarter of 2010 from Avandia and marketing settlements. GSK settled 10,000 Avandia lawsuits for a combined $460 million. Also, the company hit number three on FiercePharma's Top Layoffs of 2010 list with 5,201 jobs lost. While other companies look towards more spinoffs, GSK has focused on emerging markets as its ticket to higher revenue. It purchased Laboratorios Phoenix in 2009 and China's MeiRui in 2010; the UK-based company said the impact of its layoffs would be masked by more job opportunities in Asia and South America.

In early 2011, GSK and Human Genome Sciences gained FDA approval for Benlysta, the first new lupus treatment in more than 50 years, and experts believe it could be a $3 billion to $5 billion worldwide sales heyday for the partnership. But the FDA denied an extended approval and a potential $1 billion in sales to GSK from the prostate drug Avodart. While the drug was effective against low-risk malignant tumors, it potentially heightened the risk of developing more aggressive tumors.

GSK spun off its HIV treatments into ViiV Healthcare in 2009, combining it with Pfizer's former R&D efforts in the field. ViiV markets Ziagen, Trizivir, Epzicom and abacavir as part of its suite of drugs for HIV/AIDS.



Latest Headlines

Latest Headlines

Isis and GlaxoSmithKline eye Phase III with a rare disease drug

GlaxoSmithKline and partner Isis Pharmaceuticals are plotting a pivotal trial in the rare TTR amyloid cardiomyopathy, an inherited disease that impairs the heart muscle.

J&J and ViiV's long-acting HIV treatment stacks up to daily pills in Phase II

A new semimonthly treatment from Johnson & Johnson and ViiV Healthcare tamped down HIV as well as daily therapy in a midstage trial, promising a more convenient option for patients.

GSK forms Keytruda combo trial pact as it plots path to 20 filings by 2020

GlaxoSmithKline has struck a deal to trial its anti-OX40 monoclonal antibody in combination with Merck's Keytruda. The Phase I study is part of a slate of programs that GSK is hoping will support filings for up to 20 new drug approvals in the coming years, the success rate of which will go a long way to deciding whether the company can bounce back from its recent travails.

Pfizer flirted with a GSK megabid but got rejected: FT

Pfizer admits it's wooing Allergan for a merger worth more than $100 billion. But what it's not saying publicly is that GlaxoSmithKline has rejected its advances. That's the word from the Financial Times, whose sources say Pfizer had been flirting with a GSK buy, but the U.K.-based drugmaker wasn't impressed. Pfizer duly backed away.

UPDATED: GSK readies respiratory sales force to challenge Xolair in severe asthma

GlaxoSmithKline's respiratory unit is gearing up for a sunnier 2016--one that includes stellar coverage for its meds and a slowdown on Advair's price decline, CEO Andrew Witty said Wednesday. It's also ready to add a U.S. launch for new product Nucala to that list, and it'll find out soon whether it has the green light to do just that.

The top 10 biopharma pipeline disasters of 2015

Drug R&D is a tough business. The odds are almost always against success, and the price to be paid for being wrong is cruelly high. That said, it did seem a little harder than usual this year to...

GSK chief: We don't need a breakup or a Pfizer deal. Just look at ViiV's sales surge

GlaxoSmithKline surpassed Wall Street's earnings estimates in Q3, with lower spending in vaccines and consumer health largely driving the beat. But that's not to say it didn't turn in a couple of standout sales performances.

GSK reports PhIII success for shingles jab, will file for approval in late 2016

Merck's Zostavax is the only shingles vaccine approved in the U.S. and EU, but it may not be for long. Based on results from two Phase III trials involving more than 16,000 older adults, GlaxoSmithKline plans to submit a regulatory filing for its shingles candidate, dubbed Shingrix, in North America, Japan and the EU in the second half of 2016.

GSK's malaria vaccine hits roadblock as WHO recommends pilot projects

The World Health Organization is throwing a roadblock in GlaxoSmithKline's plans to roll out its malaria vaccine, dubbed RTS,S or Mosquirix, by calling for the vaccine to be used in pilot projects before a widespread campaign. Such pilot projects can take up to 5 years to complete.

GlaxoSmithKline's cardio R&D group records another big PhIII flop

More than a year after its second big Phase III program for darapladib also turned out to be a bust, GlaxoSmithKline is reporting today that losmapimod--cited by CEO Andrew Witty as a top late-stage program--failed to measure up in the first leg of a clinical marathon. And it's not planning to fund step two.